Discovery of a novel aminoglycoside antibiotic, TS2037, and its potent antibacterial activity Deliverables from collaboration with Institute of Microbial Chemistry

Abstract

Collaboration between Institute of Microbial Chemistry and Meiji Seika Pharma has a long history in the field of research and development of novel aminoglycoside antibiotics. In this review article, summary of selected output from the above collaboration is disclosed and discovery and biological activities of a novel aminoglycoside antibiotic generated from the collaboration, TS2037, are described. TS2037 exhibited stronger in vitro antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa compared with all clinically useful aminoglycoside antibiotics. Moreover the clinical efficacy of TS2037 against MRSA or P. aeruginosa infection was estimated by evaluation in application of clinical isolates. Strong protective effects of TS2037 against systemic infections in mice caused by MRSA or P. aeruginosa are also reported.